BR112012017938A2 - métodos e usos referentes á identificação de composto envolvido em dor bem como métodos para diagnosticar algesia - Google Patents

métodos e usos referentes á identificação de composto envolvido em dor bem como métodos para diagnosticar algesia

Info

Publication number
BR112012017938A2
BR112012017938A2 BR112012017938A BR112012017938A BR112012017938A2 BR 112012017938 A2 BR112012017938 A2 BR 112012017938A2 BR 112012017938 A BR112012017938 A BR 112012017938A BR 112012017938 A BR112012017938 A BR 112012017938A BR 112012017938 A2 BR112012017938 A2 BR 112012017938A2
Authority
BR
Brazil
Prior art keywords
methods
pain
diagnosing
well
identification
Prior art date
Application number
BR112012017938A
Other languages
English (en)
Inventor
M Schulte Anke
Metz Weidmann Christiane
Ziemek Daniel
Ding Pfennigdorf Danping
Michaelis Martin
Gebauer Mathias
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112012017938A2 publication Critical patent/BR112012017938A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

métodos e usos referentes á identificação de composto envolvido em dor bem como métodos para diagnosticar algesia. a presente invenção refere-se a um método para identificar um composto envolvido em dor, o uso do ácido nucleico llrg ou proteína ll2rg parar identificar um composto envolvido em dor, bem como métodos para diagnosticar algesia envolvendo o mesmo.
BR112012017938A 2010-01-21 2011-01-20 métodos e usos referentes á identificação de composto envolvido em dor bem como métodos para diagnosticar algesia BR112012017938A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305068A EP2348129A1 (en) 2010-01-21 2010-01-21 Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
PCT/EP2011/050776 WO2011089192A1 (en) 2010-01-21 2011-01-20 Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia

Publications (1)

Publication Number Publication Date
BR112012017938A2 true BR112012017938A2 (pt) 2017-06-27

Family

ID=42115310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017938A BR112012017938A2 (pt) 2010-01-21 2011-01-20 métodos e usos referentes á identificação de composto envolvido em dor bem como métodos para diagnosticar algesia

Country Status (13)

Country Link
US (1) US20130059745A1 (pt)
EP (2) EP2348129A1 (pt)
JP (1) JP2013517759A (pt)
KR (1) KR20120128634A (pt)
CN (1) CN102803514A (pt)
AU (1) AU2011208728A1 (pt)
BR (1) BR112012017938A2 (pt)
CA (1) CA2786961A1 (pt)
IL (1) IL220827A0 (pt)
MX (1) MX2012008362A (pt)
RU (1) RU2012135297A (pt)
SG (1) SG182650A1 (pt)
WO (1) WO2011089192A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI963989A (fi) 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
GB2377940A (en) * 2001-07-27 2003-01-29 Warner Lambert Co Identification and use of molecules implicated in pain
US20030216341A1 (en) * 2002-02-14 2003-11-20 Hermann Lubbert Multiple genes relevant for the characterization, diagnosis, and manipulation of neuropathic pain
EP1336661A1 (en) * 2002-02-14 2003-08-20 Biofrontera Pharmaceuticals AG Multiple genes relevant for the characterisation, diagnosis, and manipulation of neuropatic pain
WO2005043973A2 (en) * 2003-10-28 2005-05-19 Janssen Pharmaceutica Nv Assay systems and methods for detecting molecules that interact with sk2 channels
MX2007009562A (es) * 2005-02-18 2008-03-11 Gov Health & Human Serv Identificacion de marcadores de diagnostico moleculares para endometriosis en linfocitos sanguineos.
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof

Also Published As

Publication number Publication date
CA2786961A1 (en) 2011-07-28
SG182650A1 (en) 2012-08-30
JP2013517759A (ja) 2013-05-20
EP2348129A1 (en) 2011-07-27
RU2012135297A (ru) 2014-02-27
CN102803514A (zh) 2012-11-28
EP2526204A1 (en) 2012-11-28
IL220827A0 (en) 2012-08-30
AU2011208728A1 (en) 2012-08-09
MX2012008362A (es) 2012-08-08
US20130059745A1 (en) 2013-03-07
KR20120128634A (ko) 2012-11-27
WO2011089192A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
EA201590027A1 (ru) Способы детекции заболеваний или состояний
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
WO2014145820A3 (en) Multiple tagging of long dna fragments
BR112012008173A2 (pt) molécula de ligação específica de rsv
DK2859017T3 (da) Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
IN2015DN01300A (pt)
BR112012009854A8 (pt) proteínas de ligação de antígeno il-23 humana
DK3581662T3 (da) Sammensætninger og fremgangsmåder til detektering og identificering af nukleinsyresekvenser i biologiske prøver
BR112015022821A2 (pt) método para avaliar status renal em um indivíduo e kit de ensaio de diagnóstico
BR112012025470A2 (pt) sistema para reconstruir informações cardíacas, montagem para facilitar a reconstruçã de informações cardíacas, e método para reconstrução de informações cardíacas
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112013024574A2 (pt) polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
WO2012134602A3 (en) Methods and systems for sequencing long nucleic acids
ITMI20110357A1 (it) Sistema microfluidico per scopi di analisi e di diagnosi, nonchè corrispondente procedimento per produrre un sistema microfluidico
GB201219137D0 (en) Direct nucleic acid amplification kit, reagent and method
BRPI0719879A8 (pt) sal de adição de ácido, processo para sua preparação e seu uso, bem como intermediário químico
ITRM20120383A1 (it) Metodo e kit per la rivelazione di anticorpi.
DE112010000972A5 (de) Vorrichtung für eine Übertragung von Drehmomenten
IN2015DN02479A (pt)
EP2841599A4 (en) METHOD OF IDENTIFYING AGENTS FOR INDUCTING RESPIRATORY SENSITIZATION, AND ARRANGEMENT AND ANALYSIS KITS FOR USE IN THE METHOD
BR112014008089A2 (pt) método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método
BR112013030886A2 (pt) método, reagente e kit para medir hemoglobina glicada.
BRPI0815378A2 (pt) as160 como proteína do tipo as160, sistemas de teste, métodos e usos envolvendo a mesma para identificação de terapêutica para diabetes tipo 2
FI20090161A0 (fi) Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]